Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q4 2022 (← Previous) (Next →)

Filing Date: Feb 9, 2023

Total Value ($000): $48,328 (100.0% shares, 0.0% debt)

Holdings (7)

CRSP CRISPR Therapeutics AG 41.9%

Value ($000) $20,266 Shares 498,558 Est. Cost $40.26 Unrealized +31.8%

— Gritstone Oncology, Inc. 25.4%

Value ($000) $12,286 Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— Passage Bio, Inc. 14.2%

Value ($000) $6,844 Shares 4,959,769 Est. Cost $17.48 Unrealized —

— CymaBay Therapeutics, Inc. 7.1%

Value ($000) $3,409 Shares 543,753 Est. Cost $9871.60 Unrealized —

— Adverum Biotechnologies, Inc. 6.1%

Value ($000) $2,937 Shares 5,068,233 Est. Cost $9646.10 Unrealized —

— Aligos Therapeutics, Inc. 4.6%

Value ($000) $2,211 Shares 2,320,381 Est. Cost $27.65 Unrealized —

— Minerva Surgical Inc. 0.8%

Value ($000) $374 Shares 1,673,700 Est. Cost $5.14 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	498,558	$20,266	41.9%	$40.26	+31.8%	Common Shares	H17182108
—	Gritstone Oncology, Inc.	3,561,150	$12,286	25.4%	$7767.86	—	Common Stock	39868T105
—	Passage Bio, Inc.	4,959,769	$6,844	14.2%	$17.48	—	Common Stock	702712100
—	CymaBay Therapeutics, Inc.	543,753	$3,409	7.1%	$9871.60	—	Common Stock	23257D103
—	Adverum Biotechnologies, Inc.	5,068,233	$2,937	6.1%	$9646.10	—	Common Stock	00773U108
—	Aligos Therapeutics, Inc.	2,320,381	$2,211	4.6%	$27.65	—	Common Stock	01626L105
—	Minerva Surgical Inc.	1,673,700	$374	0.8%	$5.14	—	Common Stock	60343F106